NYSE:AGN - Allergan Stock Price, Forecast & News

Allergan trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."

Allergan announced a quarterly dividend on Friday, January 24th. Shareholders of record on Friday, February 14th will be paid a dividend of $0.74 per share on Friday, March 13th. This represents a $2.96 dividend on an annualized basis and a dividend yield of 1.50%. The ex-dividend date is Thursday, February 13th. View Allergan's Dividend History.

Allergan announced that its Board of Directors has initiated a share repurchase program on Tuesday, January 29th 2019, which authorizes the company to buyback $2,000,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to buy up to 4.1% of its shares through open market purchases. Shares buyback programs are usually a sign that the company's board believes its shares are undervalued.

Allergan plc (NYSE:AGN) issued its quarterly earnings results on Monday, February, 10th. The company reported $5.22 EPS for the quarter, beating the consensus estimate of $4.57 by $0.65. The business earned $4.35 billion during the quarter, compared to analysts' expectations of $4.09 billion. Allergan had a negative net margin of 32.76% and a positive return on equity of 9.82%. The business's revenue for the quarter was up 6.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $4.29 EPS. View Allergan's Earnings History.

Allergan is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for Allergan.

19 equities research analysts have issued 1-year price objectives for Allergan's stock. Their forecasts range from $144.95 to $203.00. On average, they expect Allergan's stock price to reach $178.72 in the next year. This suggests that the stock has a possible downside of 9.6%. View Analyst Price Targets for Allergan.

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allergan in the last year. There are currently 16 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Allergan.

Media headlines about AGN stock have been trending extremely negative on Tuesday, InfoTrie reports. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Allergan earned a news sentiment score of -5.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Allergan.

Allergan saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 15,400,000 shares, an increase of 5.6% from the January 15th total of 14,580,000 shares. Based on an average daily volume of 2,360,000 shares, the days-to-cover ratio is presently 6.5 days. Currently, 4.7% of the company's shares are sold short. View Allergan's Current Options Chain.

Some companies that are related to Allergan include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), The Medicines (MDCO), Horizon Therapeutics (HZNP), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX) and Corcept Therapeutics (CORT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Allergan investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Micron Technology (MU), Aegean Marine Petroleum Network (ANW), NIC (EGOV), Transocean (RIG) and United Rentals (URI).

Allergan's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include State Street Corp (4.39%), Franklin Resources Inc. (2.24%), Longview Partners Guernsey LTD (2.10%), Renaissance Technologies LLC (1.53%), Bank of New York Mellon Corp (0.77%) and TIG Advisors LLC (0.68%). Company insiders that own Allergan stock include Brent L Saunders, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado, Matthew M Walsh and William Meury. View Institutional Ownership Trends for Allergan.

AGN stock was sold by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, Assenagon Asset Management S.A., Fred Alger Management LLC, MUFG Securities EMEA plc, State Street Corp, Janus Henderson Group PLC, FMR LLC and Fir Tree Capital Management LP. View Insider Buying and Selling for Allergan.

AGN stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp, Segantii Capital Management Ltd, Bank of Montreal Can, Beryl Capital Management LLC, Laurion Capital Management LP, FIL Ltd and Vivaldi Asset Management LLC. Company insiders that have bought Allergan stock in the last two years include Brent L Saunders, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado and Matthew M Walsh. View Insider Buying and Selling for Allergan.

Shares of AGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AGN stock can currently be purchased for approximately $197.60.

Allergan has a market capitalization of $64.87 billion and generates $16.09 billion in revenue each year. The company earns $-5,271,000,000.00 in net income (profit) each year or $17.64 on an earnings per share basis. Allergan employs 16,900 workers across the globe.View Additional Information About Allergan.

The official website for Allergan is http://www.allergan.com/.

Allergan's mailing address is CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400. The company can be reached via phone at 862-261-7000 or via email at [email protected]